SEC Form 4 · accession 0001144204-17-051545
Moleculin Biotech, Inc. · MBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan P. Foster
Officer — Chief Financial Officer
Period of report
Oct 3, 2017
Accepted (ET)
Oct 5, 2017 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001659617
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2,F1 | $2.49 | Oct 3, 2017 | A | 145,000 | A | — | Oct 3, 2027 | Common stock | 145,000 | 545,000 | D |
Explanation of responses
- F1The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
- F2Issued in connection with the reporting person's employment with the Company.